Dermatologicals in Taiwan - Research and Markets

Dermatologicals is expected to continue to register muted current value growth in 2022 even with a significant number of COVID-19 suffered reporting skin problems as a sequela. Many also reported skin problems such as rashes or allergic reactions following COVID-19 vaccination. In general, Taiwanese people tend to seek skin care solutions from medical institutions, including private clinics and hospitals, rather than self-medicating. This continues to limit growth in this category in 2022.

The Dermatologicals in Taiwan report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2017-2021, allowing you to identify the sectors driving growth. Forecasts to 2026 illustrate how the market is set to change.

Product coverage: Antiparasitics/Lice (Head and Body) Treatments, Antipruritics, Cold Sore Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Dermatologicals, Topical Allergy Remedies/Antihistamines, Topical Antifungals, Topical Germicidals/Antiseptics, Vaginal Antifungals.

Data coverage: Market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?

Get a detailed picture of the Dermatologicals market;
Pinpoint growth sectors and identify factors driving change;
Understand the competitive environment, the market’s major players and leading brands;
Use five-year forecasts to assess how the market is predicted to develop.

DERMATOLOGICALS IN TAIWANKEY DATA FINDINGS

2022 DEVELOPMENTS

Limited trust in self-diagnosis for skin issues keeps dermatologicals growth small
Despite COVID-19 hair loss symptoms, hair loss treatments sees small growth due to lack of marketing and promotion
Competitive landscape remains stable with GSK maintaining its newly won share

PROSPECTS AND OPPORTUNITIES

Despite support from ageing population, category growth will remain muted
Climate change contributes to value sales
Johnson & Johnson’s popular paediatric product (baby powder) will be replaced due to the ingredient dispute

CATEGORY DATA

Table 1 Sales of Dermatologicals by Category: Value 2017-2022
Table 2 Sales of Dermatologicals by Category: % Value Growth 2017-2022
Table 3 NBO Company Shares of Dermatologicals: % Value 2018-2022
Table 4 LBN Brand Shares of Dermatologicals: % Value 2019-2022
Table 5 LBN Brand Shares of Hair Loss Treatments: % Value 2019-2022
Table 6 Forecast Sales of Dermatologicals by Category: Value 2022-2027
Table 7 Forecast Sales of Dermatologicals by Category: % Value Growth 2022-2027

CONSUMER HEALTH IN TAIWAN

EXECUTIVE SUMMARY

Consumer health in 2022: The big picture
2022 key trends
Competitive landscape
Retailing developments
What next for consumer health?

MARKET INDICATORS

Table 8 Consumer Expenditure on Health Goods and Medical Services: Value 2017-2022
Table 9 Life Expectancy at Birth 2017-2022

MARKET DATA

Table 10 Sales of Consumer Health by Category: Value 2017-2022
Table 11 Sales of Consumer Health by Category: % Value Growth 2017-2022
Table 12 NBO Company Shares of Consumer Health: % Value 2018-2022
Table 13 LBN Brand Shares of Consumer Health: % Value 2019-2022
Table 14 Penetration of Private Label in Consumer Health by Category: % Value 2017-2022
Table 15 Distribution of Consumer Health by Format: % Value 2017-2022
Table 16 Distribution of Consumer Health by Format and Category: % Value 2022
Table 17 Forecast Sales of Consumer Health by Category: Value 2022-2027
Table 18 Forecast Sales of Consumer Health by Category: % Value Growth 2022-2027

APPENDIX